The news: An FDA advisory panel narrowly voted to allow US compounding pharmacies to produce five peptides that were previously barred from compounding, including the popular BPC-157, which is typically used for accelerating tissue and joint repair. The committee will vote on additional peptides Friday, with results pending at the time of writing. The recommendations are nonbinding, and the FDA will make the final decision on whether to lift current restrictions. The peptides under consideration would be prescription-only products and would still not be FDA-approved.

Why it matters: Wellness peptides (often promoted for injury recovery, weight loss, muscle gain, and anti-aging) are already popular even though most lack human testing and aren’t legally marketed as consumer health products.

If the FDA adopts the panel's recommendations, the peptide market would shift from a largely gray and black market to one with greater legitimacy. Compounding pharmacies would be able to legally produce certain peptides, similar to compounded weight loss drugs. Today, consumers obtain peptides through unauthorized channels including compounding pharmacies (despite current FDA restrictions), social media apps, wellness clinics, overseas suppliers, and even third-party Amazon sellers. Some products may also be mislabeled or deceptively marketed, raising the risk that consumers receive something other than what they expect.

Medical experts remain deeply concerned about consumer use of wellness peptides, even if the FDA accepts the panel's recommendations. The vote does not change the limited clinical evidence or unresolved safety risks surrounding peptides. FDA scientists even urged the panel to reject the proposal, and Kennedy has faced criticism for appointing committee members with ties to the peptide industry. Most healthcare professionals want to see more (or any) published evidence that peptides are safe for humans. Some 95% of clinicians express some concerns about patient use of peptides even if broader access expands, primarily citing self-treatment without medical oversight (33%) and side effects and safety risks (30%), according to a May Sermo survey.

Implications for telehealth and wellness brands: Telehealth platforms including Hims & Hers and Noom have been preparing for this, acquiring compounding facilities with plans to produce and offer peptides to consumers. These companies are well positioned because they can combine medical oversight, convenient access, regulated production partners, and credible consumer brands.

At the same time, greater legitimacy will accelerate peptide adoption. As consumers shift from gray and black market sellers to mainstream telehealth platforms, more patients will be exposed to the same safety risks that have long concerned physicians. Companies entering the peptide market will need to go beyond current compounding requirements by clearly communicating risks, providing prominent safety and side effect warnings, implementing robust patient screening protocols, and steering consumers away from misleading peptide information circulating on social media, online forums, and unverified sellers.